US EditionMonthly Obesity Shot Shows Big Weight Loss in Trial
- Amgen reported that a monthly injection of MariTide helped obese participants lose up to 20% of body weight over a year in a phase 2 trial.
- This trial included nearly 600 adults with obesity, some with type 2 diabetes, and used a placebo group that lost only about 2.5% of weight on average.
- The treatment also improved glycemic control by lowering A1C by up to 2.2 percentage points and showed benefits for blood pressure, cholesterol, and inflammation.
- Dr. Jay Bradner noted participants’ weight loss had not plateaued after a year, while Dr. Shauna Levy emphasized the need for multiple treatment options due to obesity’s complexity.
- Following these positive outcomes, Amgen plans a 72-week phase 3 trial to assess longer-term effects and optimal dosing of MariTide for obesity treatment.
25 Articles
25 Articles
Monthly obesity shot shows big weight loss in trial
Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed about 20% of their body weight over a year, researchers reported Monday in The New England Journal of Medicine.
InsideNoVA.com
Monthly Obesity Shot Shows Big Weight Loss in Trial
Key Takeaways
News Medical
MSNOnce-monthly obesity injection shows double-digit weight loss in major clinical trial
Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with or without diabetes, in a phase 2 randomized trial. The drug demonstrated an acceptable safety profile and supports further study in phase 3 trials.
A once-monthly jab cuts body weight by 16% in groundbreaking obesity trial
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful treatment for obesity. With just a once-monthly shot of 'MariTide,' participants in the study lost as much as 16% of their body weight over the course of a year.Continue ReadingCategory: Obesity, Illnesses and conditions, Body & MindTags: Obesity, Weight Loss, Weight, GLP-1 receptor agonists
Coverage Details
Bias Distribution
- 54% of the sources are Center
To view factuality data please Upgrade to Premium
